2025 Global Medical Device Top 100 Rankings Released: Medtronic and Johnson & Johnson Continue to Lead, Mindray and MicroPort Make the List

Deep News
Sep 19, 2025

On September 18, the medical device industry website Medical Design & Outsourcing published the 2025 Global Medical Device Company Top 100 Rankings (Medtech Big 100). Among the top ten positions, American companies continue to maintain absolute dominance: Medtronic PLC and Johnson & Johnson MedTech retained their first and second positions respectively; Medline Industries surpassed Siemens Healthineers to rise to third place; Boston Scientific climbed 2 positions to 9th place; BD Medical (Medical and Interventional business) advanced from 12th to 10th position.

Two Chinese companies made this year's rankings:

Mindray Medical Ranking: 25th (↑2) Revenue: $5.01 billion (fiscal year ending December 31, 2024) R&D Investment: $557 million

As China's leading medical device company, Mindray Medical delivered its first interim report showing both revenue and net profit declines since its A-share listing in 2018 for the first half of 2025: revenue of RMB 16.743 billion, down 18.45% year-over-year; attributable net profit of RMB 5.069 billion, down 32.96% year-over-year. Market sources indicate that Mindray is considering a secondary listing in Hong Kong, seeking to raise at least $1 billion, with HTSC and JPMorgan Chase already selected as underwriters.

MicroPort Medical Ranking: 70th (↑3) Revenue: $1.03 billion (fiscal year ending December 31, 2024) R&D Investment: $217 million

MicroPort Medical achieved a key turnaround in the first half of 2025: under non-Hong Kong Financial Reporting Standards, the company recorded an adjusted profit of $1.221 million, compared to a loss of $64.074 million in the same period last year; EBITDA reached $128 million, up 116.2% year-over-year; first-half losses narrowed to $46.6 million (compared to $96.83 million in the same period last year). On the day of the earnings announcement, the company's stock price surged 19.57% in the afternoon session. The performance improvement was primarily attributed to strong overseas market performance, with overseas revenue growing 85% year-over-year in 2024.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10